Amgen will acquire Alantos, a private company developing drugs for diabetes and inflammatory diseases, for $300 million in cash. Alantos’ lead drug candidate, ALS 2-0426, is a DPP-IV inhibitor in Phase IIa development for the treatment of type II diabetes. Under terms of the agreement, Alantos will become a wholly-owned subsidiary of Amgen. The acquisition has been approved by the boards of directors of each company and the shareholders of Alantos. Subject to customary closing conditi...